Browse Tag

in-depth

51 Articles

$Axi-cel in relapsed or refractory large B-cell lymphoma$

ICML 2023

Axi-cel in relapsed or refractory large B-cell lymphoma

June 23, 2023

Dr Jason Westin, hematologist at Texas MD Anderson Cancer Center, Houston gives...

ICML 2023

Role of BTK-inhibitors in B-cell malignancies

June 22, 2023

Prof. Stephan Stilgenbauer, hematologist at the Ulm University in Germany...

ICML 2023

The SELENE study

June 22, 2023

Prof. Ann Janssens, hematologist at UZ Leuven, discusses the outcomes of the...

EHA 2023

The therapeutic revolution for the management of multiple myeloma

June 15, 2023

Dr. Claudio Cerchione, Istituto Scientifico Romagnolo per lo Studio e la Cura...

EHA 2023

The phase 1/2 Bruin study

June 14, 2023

Prof. Wojciech Jurczak discussed the data from the phase 1 / 2 Bruin study...

EHA 2023

In the spotlight: Jan Cools, editor-in-chief of HemaSphere

June 13, 2023

MediMix had an interview with Prof. Jan Cools from KU Leuven and...

EHA 2023

The unmet need in patients with multiple myeloma at first relapse

June 12, 2023

Prof. Maria Victoria Mateos, hematologist at the Hospital Universitario De...

EHA 2023

BTK inhibitors as first line treatment in mantle cell lymphoma: a debate

June 11, 2023

Dr. Jeanette Doorduijn, hematologist at the Erasme hospital in Rotterdam...

EHA 2023

Diagnosis and treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)

June 10, 2023

Dr. Claudio Cerchione, Istituto Scientifico Romagnolo per lo Studio e la Cura...

EHA 2023

José Carreras Award: Ph+ ALL, from the worst malignancy to a chemo/transplant-free management

June 9, 2023

Dr. Tim Pieters discussed his research focusing on modelling of blood cancers...